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 Cell therapy for treatment of renal failure in the acute setting has proved successful 
with therapeutic impact, yet development of a sustainable, portable bioartificial 
kidney for treatment of chronic renal failure has yet to be realized. Challenges in 
maintaining an anticoagulated blood circuit, the typical platform for solute 
clearance and support of the biological components, have posed a major hurdle in 
advancement of this technology. Our group has developed a Bioartificial Renal 
Epithelial Cell System (BRECS) capable of differentiated renal cell function while 
sustained by body fluids other than blood. To evaluate this device for potential use 
in end stage renal disease, we established a large animal model that exploits 
peritoneal dialysis fluid for support of the biologic device and delivery of cell 
therapy while providing uremic control. Anephric sheep received a continuous flow 
peritoneal dialysis (CFPD) circuit that included a BRECS. Sheep were treated with 
BRECS containing 1x108 renal epithelial cells or acellular sham devices for up to 7 
days. BRECS cell viability and activity were maintained with extracorporeal 
peritoneal fluid circulation. A systemic immunologic effect of BRECS therapy was 
observed as cell treated sheep retained neutrophil oxidative activity better than 
sham treated animals. This model demonstrates that use of the BRECS within a 
CFPD circuit embodies a feasible approach to a sustainable and effective wearable 
bioartificial kidney.  
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1. INTRODUCTION      
Renal replacement therapy (RRT) using hemodialysis or peritoneal dialysis (PD) 
has become a mainstay therapy for patients with End Stage Renal Disease 
(ESRD). Although this approach is life sustaining, it remains suboptimal with poor 
clinical outcomes. Current RRT utilize semipermeable membranes to substitute for 
the small solute clearance function of the renal glomerulus but they do not replace 
the transport, metabolic, and endocrinologic functions of the tubular cells, 
rendering them only partial substitutive therapy at best. The better outcomes in 
patients treated with kidney transplant compared to chronic dialysis emphasizes 
the benefits of full renal replacement for ESRD (US Renal Data System 2008; 
Tonelli et al. 2011). 
   Renal cell therapy incorporated into conventional RRT has shown metabolic, 
immunologic and survival benefits in acute renal failure (ARF) in preclinical (Humes 
et al. 1999; Humes et al. 2002; Humes et al. 2003a; Fissell et al. 2003; Huijuan et 
al. 2007; Wang et al. 2010; Westover et al. 2014) and clinical studies (Humes et al. 
2003b; Humes et al. 2004; Tumlin et al. 2008). The first renal cell therapy device 
used in patients with ARF, the Renal Assist Device (RAD), demonstrated that 
allogeneic renal epithelial cells (REC) maintained within an extracorporeal 
environment could provide therapeutic benefit to patients requiring continuous RRT 
and improve survival (Humes et al. 2004; Tumlin et al. 2008). The limitations of cell 
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expansion and device design made manufacture, storage, and distribution of the 
RAD a challenge to meet clinical demand. Enhanced REC propagation 
methodologies (Westover et al. 2012), along with improved fabrication techniques 
have overcome these challenges giving rise to a second generation device, the 
Bioartificial Renal Epithelial Cell System (BRECS), which was designed to 
surmount a number of obstacles preventing widespread use of cell based 
therapies. This approach resulted in the ability to maintain a dense population of 
REC within a compact, portable and cryopreservable format for on-demand 
deployment in clinical situations (Buffington et al. 2012). The BRECS is a 
bioreactor containing adult REC seeded onto porous carbon disks within a 
polycarbonate housing. Cell viability is maintained by perfusion culture through the 
disks, allowing cells to respond to alterations in the perfusate milieu, potentially 
releasing metabolic and endocrinologic products with therapeutic value. 
   In addition to previously mentioned limitations for global use of cell enhanced 
therapies, the difficulty in maintaining continuous extracorporeal blood circulation 
without thrombosis, despite continuous anticoagulation strategies, remains an 
impediment to development of a sustainable portable cell device for treatment of 
ESRD. Elimination of the blood circuit inherent to hemodialysis based therapies 
could facilitate delivery. To this end, a wearable bioartificial kidney (WeBAK) that 
exploits peritoneal fluid to maintain oxygen and nutrient delivery to a BRECS was 
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conceived and tested in an ovine model. BRECS devices were monitored during 
and after extracorporeal culture and serial blood sampling was performed on sheep 
to assess metabolic, endocrinologic and immunologic impact of BRECS therapy. 
The project aimed to provide insight into the feasibility and potential impact of 
delivering renal cell therapy in this manner for treatment in ESRD. 
2. MATERIALS AND METHODS 
2.1 Bioartificial renal epithelial cell system (BRECS) 
The BRECS is comprised of porous carbon disks colonized with up to 2 x108 
human REC within a perfusable polycarbonate housing. Perfusate flows over and 
through the disks to sustain cell viability and export cell products. An injection 
molded design allows BRECS to be fitted with monitoring systems, permitting 
monitoring of temperature and oxygen consumption in real time. Total weight of a 
cell seeded and fluid filled device is approximately 62gm. 
     Primary REC were isolated and expanded from human kidneys unsuitable for 
transplantation due to anatomic or fibrotic defects (procured from the National 
Disease Research Interchange) following an established method (Westover et al. 
2012). Details of REC isolation, seeding onto carbon disks for use in BRECS units 
and maintenance of BRECS in vitro have been described (Buffington et al. 2012).  
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Metabolic activity of REC within BRECS was evaluated using oxygen consumption 
rates (OCR) and non-destructive glutathione (GSH) metabolism. Oxygen 
measurements were performed either using an i-STAT analyzer (Abbott Point of 
Care, Princeton, NJ) on media collected from closed units or by oxygen sensors. 
RedEye patches (Ocean optics, Dunedin, FL) or PSt3 patches (PreSens, 
Regensburg, Germany) were set up in recirculating, closed, oxygen impermeable 
circuits. To determine average OCR, a linear regression approximation of slope 
was used. GSH metabolism was determined by the rate of degradation of 
exogenously added GSH. BRECS were completely filled with 20µM GSH (Sigma-
Aldrich) in Ultra MDCK media and samples collected at baseline, 10 and 30 
minutes. Samples were analyzed by the method of Tietze (Tietze 1969). After 
extracorporeal culture, a qualitative assessment of cell viability was made by 
adding 1 µg/mL fluorescein diacetate and propidium iodide to individual disks from 
disassembled BRECS within well plates. Living and dead cells were visualized 
immediately with a Zeiss Axiovert 200 inverted fluorescence microscope (Carl 
Zeiss, Inc. Thornwood, NY) equipped with corresponding filter sets, and 
micrographs obtained using Zeiss AxioCam MRm and ICc1 cameras (Carl Zeiss, 
Inc.).  
 
2.4 Experimental animals and the extracorporeal WeBAK circuit 
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Animal use adhered to principles stated in the Guide for Care and Use of 
Laboratory Animals (Institute for Laboratory Animal Research, 1996) and 
procedures were performed under protocols approved by the institutional 
committee for care and use of animals at the University of Michigan. Female sheep 
(35-45 kg) were maintained under standard laboratory conditions until onset of 
continuous flow peritoneal dialysis (CFPD), during which they were confined in 
customized stanchions while connected to the extracorporeal circuit. Sheep were 
instrumented with separate ingress and egress PD catheters and nephrectomy 
was staged to permit healing around the catheters which were placed concurrent 
with removal of the first kidney. Antimicrobial and analgesic medication was 
administered peri-operatively. CFPD was instituted within 24h of complete 
nephrectomy using commercially available 4.25% glucose dialysate solution 
(Dianeal® Baxter Healthcare, Deerfield, IL) with nafcillin [100mg/L] and gentamicin 
[4mg/L] added. An intraperitoneal instillation of 2-3L dialysate was continuously 
recirculated at 80-100ml/min through a primed extracorporeal circuit of ¾” Tygon® 
tubing using a rotary pump with a segment of collapsible tubing to prevent 
generation of negative abdominal pressure (M-pump, MC3 Inc., Ann Arbor, MI). A 
polysulfone hemofilter with a 65kD molecular weight cut-off provided 
immunoisolation for the cells by generating ultra-filtered PD that was directed by a 
peristaltic single channel pump (Masterflex® Cole-Palmer, Vernon Hills IL) through 
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a fluid warming system (Hotline®, Smith Medical) at 380C for parallel perfusion of 
the BRECS (Figure 1). Total circuit volume was approximately 1000mL. Dialysate 
was refreshed by continuous flow into and out of the circuit plus daily exchanges of 
the abdominal content. BRECS containing approximately 1x108 REC or acellular 
sham devices were cultured under identical conditions in vitro prior to placement in 
an extracorporeal WeBAK circuit. Devices were deployed subsequent to dialysate 
equilibration to physiologic pH and were maintained by ex vivo perfusion with 
peritoneal fluid for up to 7 days. 
     Serum chemistry and electrolyte values were determined using automated 
veterinary analyzers (IDEXX VetTest®, IDEXX VetLyte®, IDEXX Laboratories Inc. 
USA) according to the manufacturer’s directions. Complete blood counts and 
differentials were determined by a Hemavet® analyzer (Drew Scientific, Waterbury 
CT). Neutrophil (NE) counts and quantification of intracellular reactive oxygen 
species (ROS) were assessed as markers of immunologic status. NE were isolated 
on a discontinuous Percoll gradient, incubated with the reactive dye, 5-(and 6)-
chloromethyl-2’, 7’-dichlorodihydroflourescein diacetate, acetyl ester (CM-H2D 
CFDA, Molecular Probes) [10uM] in RPMI 15min at 37°C, followed by incubation 
(+/-) phorbol-12-myristate-13-acetate (PMA) [1uM] at 37°C for 30min. NE were 
labeled with mouse-anti-bovine unconjugated CD11b (ABD Serotech) /Anti-IgG 
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conjugate mouse 647 (Life Technologies) to allow gating then fixed. Mean 
fluorescent intensity was determined using an Accuri Flow Cytometer.  
     Endocrine support by BRECS was assessed using Vitamin D3. To ensure an 
adequate source of substrate, 3000 units/day of 25-hydroxyvitamin D3 (25VitD3, 
Sigma Aldrich) was infused into the CFPD circuit pre BRECS. Sheep serum 
samples were frozen and sent to Heartland Assays, Inc. (Ames, IO) for 
quantification of 1α,25-dihydroxyvitamin D3 (1,25VitD3) by radioimmunoassay. 
 
2.9 Statistical analyses 
Comparisons between groups were made using Student’s t test assuming equal 
variance. Significance was set at p<0.05. 
 
3. Results and Discussion 
3.1 Establishing a WeBAK using CFPD in an ovine model  
Tissue engineered devices, such as the RAD and the BRECS, have revealed the 
therapeutic value in replacing the lost metabolic, endocrine and immunologic 
functions of the kidney, however impediments to long term delivery of cell therapy 
remain. As technological advancements are made in miniaturization of medical 
devices, interest in portable dialysis systems is increasing as is recognition of PD 
as a viable platform for a sustainable wearable artificial kidney (Kim and Ronco 
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2011; Davenport 2012; Armignacco et al. 2015). A large animal model of uremia 
sustained using 24h continuously recirculating CFPD was developed to 
demonstrate a WeBAK based on this modality. Pilot animals (n=13) were needed 
to establish instrumentation and PD protocols. Catheter complications were a 
primary obstacle to a recirculating CFPD regimen, with catheter dysfunction 
occurring in 23 of the 34 total animals used. Leakage of fluid around catheters and 
catheter occlusion by omental wrapping were leading causes for disruption or 
failure of CFPD. Inclusion of a purse string suture in the peritoneum at catheter 
implantation, a 14 day healing period prior to onset of PD, and Oreopoulos-
Zellerman catheters that limit omental wrapping were found to collectively minimize 
catheter malfunction in this model. Fibrin accumulation within the circuit was 
universal and the filter was replaced as needed to maintain circuit patency. Culture 
of bacteria from PD fluid of 5 pilot animals prompted empiric addition of 
antimicrobials to the dialysate. Bacterial culture of PD fluid was positive for a single 
sheep in each of the study groups, however no microbial contamination of BRECS 
units was identified, demonstrating efficacy of the WeBAK design to maintain an 
aseptic environment for the BRECS. 
     Upon surmounting the challenges of the model, a stable uremic state could be 
established with CFPD, enabling at least 9 days of study with anephric sheep 
(Figure 2). Dialysate flow rates into the circuit and to waste were set at 420 and 
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470mL/hr respectively, providing a calculated weekly creatinine clearance of 
55L/wk and ultrafiltrate generation up to 1L/day. As study aims were to determine 
feasibility and effects of maintaining the biologic device within the WeBAK, further 
characterization or optimization of dialysis efficiency using the CFPD circuit was 
not attempted. Uremic control was dependent on dialysis dose and therefore not 
different between animals treated with cellular or sham devices. 
 
3.3 Extracorporeal maintenance of BRECS 
BRECS containing approximately 1x108 REC or acellular sham devices were 
cultured under identical conditions for an average of 21±9 days in vitro according to 
BRECS protocol prior to placement in an extracorporeal WeBAK circuit. Devices 
were maintained in the WeBAK by perfusion with ultra-filtered peritoneal fluid for up 
to 7 days then returned to in vitro culture for 48h prior to dismantling for histology. 
Cell BRECS  demonstrated relatively consistent metabolic activity throughout the 
duration of extracorporeal therapy confirming that REC within the BRECS 
remained viable and metabolically active when maintained by the nutrients 
provided by CFPD. At the commencement of extracorporeal culture, OCR in 
BRECS averaged 129 nmol/min, and by day 7, average OCR was 85 nmol/min 
(Figure3A). OCR measured on days 5-7 trended toward being slightly lower than 
initial measurements; however, these values were not significantly lower (p=0.65, 
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0.53 and 0.59 for days 5-7 respectively). Non-destructive GSH degradation by γ-
glutamyltranspeptidase (γGT) was chosen as a representative measurement of 
BRECS metabolic function. γGT, expressed on the apical brush border membrane 
of renal proximal tubules, catalyzes the salvage of GSH. GSH depletion in patients 
receiving maintenance dialysis contributes to the oxidative stress of ESRD 
patients. Average GSH degradation in BRECS at day 0 was 1194 nmol/hr and 898 
nmol/hr on day 7 (Figure 3B). Both OCR and GSH degradation increased toward 
pre study values when BRECS were removed from sheep and returned to in vitro 
culture. No metabolic activity was detected in sham devices. Histologic staining of 
individual disks removed from cell BRECS at the conclusion of the therapy period 
exhibited high densities of living cells following up to 7 days of extracorporeal 
culture (Figure 4), with few dead cells. 
       
3.4 Impact of BRECS therapy 
The BRECS was designed to be the first all-in-one culture vessel, cryostorage 
device and cell therapy delivery system for clinical perfusion with either ultra-
filtered blood or body fluids. BRECS, maintained in a hematogenous circuit has 
demonstrated therapeutic impact in a preclinical model AKI (Westover et al. 2014) 
yet this delivery method has limitations, particularly for chronic indications.  With 
the ability of cells within BRECS to be sustained by ex vivo peritoneal fluid, we 
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investigated the potential therapeutic impact of cell enhanced therapy delivered in 
this manner for ESRD. 
     Anephric sheep either received cell BRECS (n=13) or sham device (n=8) 
therapy via the CFPD circuit starting day 1 post nephrectomy. Therapy was 
continuous for up to 7 days, then devices were removed and sheep sustained with 
CFPD alone for an additional 48h post therapy. Blood was sampled prior to 
removal of each kidney then at a minimum of every 48h to assess endocrinologic, 
metabolic and immunologic parameters. Inability to maintain adequate flow in the 
CFPD circuit to perfuse devices for a full 7 days caused some animals to be 
terminated before all sampling was competed therefore data was averaged over 
each of 3 phases of the study: non-uremic, therapy, and post therapy. Nine cell 
BRECS and 5 sham treated sheep completed the entire study time course. 
     VIT D3 levels were measured as an indicator of the endocrinologic support that 
could potentially be provided by the BRECS. Western blotting of isolated REC has 
confirmed the presence of 1- alpha hydroxylase, the enzyme that controls the final 
conversion of 25VIT D3 to the biologically active 1,25VIT D3. Systemic 1,25VIT D3 
levels decreased in all sheep post nephrectomy and were highly variable in uremic 
sheep over the BRECS therapy period with no difference detected between 
cohorts (data not shown). This may be attributable to seasonal (sunlight) variation 
which impacts Vitamin D kinetics and the individual animal response to exogenous 
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precursor supplementation with 25VIT D, which can increase extra-renal 1-alpha 
hydroxylase activity in whole animal systems (Richart et al. 2007). Of note, activity 
of 1-alpha hydroxylase was not detectable in BRECS under normal tissue culture 
conditions however, when phosphate was omitted from the culture media, 1-alpha 
hydroxylase activity was upregulated inside 24h (unpublished data). Further 
investigation is needed to evaluate factors that may influence delivery of Vitamin D 
by BRECS (i.e. phosphate levels in PD fluid).  
     Circulating NE counts were stable in cell BRECS treated sheep (2.88±0.35 non-
uremic, 4.20±1.44 K/uL post-therapy) while NE counts in sham treated animals 
were increased significantly at post therapy compared to the non-uremic state 
(6.26±2.0 and 3.01±0.69 K/uL respectively, p=0.017). The differences between 
cohorts were not significant at any point. Since uremia has been associated with 
NE dysfunction (Haag-Weber and Horl 1996; Anding et al. 2003), the oxidative 
activity of isolated systemic NE was assessed by quantification of intracellular 
ROS. Results are summarized in Figure 5 with values reported as mean 
fluorescent intensity ± SE both with and without PMA stimulation. ROS data were 
not available from 4 of the cell treated sheep. The pre therapy values (basal and 
stimulated) were not different between groups. Basal ROS level was maintained 
and the ROS production of stimulated NE was significantly greater in sheep 
receiving BRECS cell treatment both during (Cell 198 +/- 69, Sham 64 +/- 20, 
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p=0.033) and post therapy (Cell 232 +/- 64, Sham 37+/- 14, p=0.003). Exclusion of 
immunologic data from the 2 sheep with septic peritonitis did not significantly alter 
these findings. 
 
4. Conclusions 
The BRECS offers the possibility of full renal replacement therapy by providing the 
transport, endocrine, metabolic and immunologic activity that is lacking in 
conventional dialysis modalities. BRECS therapy has demonstrated therapeutic 
benefit in a preclinical model of AKI and BRECS design overcomes a number of 
obstacles that have deterred clinical administration of renal cell therapy. A key 
feature of BRECS is the ability for maintaining the cells using body fluids other than 
blood. Renewed interest in utilization of PD as the basis for an artificial kidney with 
increased longevity and portability for chronic indications lends a platform for 
employment of the BRECS to provide cell therapy for patients with ESRD. In this 
study, we showed that a CFPD regimen was able to manage the uremic state of 
anephric sheep plus sustain cellular viability and functionality within BRECS as 
evidenced by oxygen consumption and glutathione metabolism during therapy. 
Viability stains post-therapy confirmed REC survival when maintained in this 
manner for up to 7 days. These experiments demonstrate proof of concept of a 
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WeBAK, free from the constraints of an anticoagulated blood circuit, to provide 
cellular enhanced therapy for chronic renal failure indications.  
     Fluid dynamics of the BRECS have been optimized so that perfusion rates as 
low as 10mL/min are able to provide adequate nutrient and oxygen delivery to cells 
for survival without the use of an oxygenator. Lower metabolic output by REC 
within BRECS, though not statistically significant, was observed over the one week 
course of WeBAK therapy in this model. Correlation of GSH metabolism in BRECS 
and cell number via DNA isolation (reported previously) suggests the reduction of 
metabolic output likely was due to a combination of viable cell loss along with lower 
metabolism by the remaining cells when maintained with peritoneal dialysis 
perfusate. A decrease in oxygen consumption is also likely a combination of fewer 
cells consuming oxygen at a lower rate and there may be some shift from aerobic 
to anaerobic metabolism. Further investigation is needed to determine if metabolic 
output from BRECS during extracorporeal culture is predictably altered and to 
determine if the changes in metabolic output have therapeutic implications. Of 
note, we have since found that including a segment of oxygen permeable silicone 
tubing pre-BRECS can increase the oxygen tension in the perfusate to 
approximate room air however studies are need to determine if this modification 
has any effect on metabolic output from BRECS during ex vivo perfusion with PD 
fluid. 
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     While the importance of renal tubule cells in glutathione metabolism and 
activation of Vitamin D3 and are well described, these cells also possess a less 
recognized, but important role in immunoregulatory function. Demonstrated 
immunologic effects of renal cell therapy in the setting of AKI have included 
differences in plasma cytokine concentrations, alterations in release of cytokines 
from isolated leukocytes and improved survival of sepsis (Humes et al. 1999; 
Humes et al. 2002; Fissell et al. 2003; Humes et al. 2003; Humes et al. 2003; 
Humes et al. 2004; Huijuan et al. 2007; Westover et al. 2014). Concomitant 
immune activation, systemic inflammation and immune deficiency have been linked 
with ESRD (Kato et al. 2008; Vaziri et al. 2012; Betjes 2013). Uremia appears to 
impair the phagocytic and killing functions of circulating granulocytes (Porter et al. 
1997; Anding et al. 2003; Sardenberg et al. 2006; Vaziri et al. 2012) although 
conflicting results about the generation of ROS by NE isolated from ESRD patients, 
particularly among those receiving different dialysis modalities, have been 
described (Porter et al. 1997; Anding et al. 2003; Morena et al. 2005; Sardenberg 
et al. 2006; Yoon et al. 2007). Infection is the second most common cause of death 
in ESRD, approaching 25% of annual mortality rate in hemodialysis patients (U.S. 
Renal Data System 2003). This infection complication rate is not diminished with 
higher dialysis dose or high flux membrane utilization. In this project, it was found 
that basal ROS production of isolated NE declined in sheep over the uremic time 
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course but was better maintained in the animals receiving cell therapy. Moreover, 
NE counts remained stable and the stimulated oxidative potential of NE was 
retained during and after BRECS treatment signifying that the ability to have an 
appropriate immune response to stimuli may be preserved with REC therapy.  
     The results of this preliminary study demonstrate that a 24h CFPD regimen is 
able to provide a stable uremic state in nephrectomized sheep. A BRECS is readily 
incorporated into an extracorporeal CFPD circuit using peritoneal fluid for perfusion 
of the device, providing cell survival and maintenance of function while eliminating 
the requirement for an anticoagulated blood circuit. Cell therapy using BRECS 
contributes to improved immunologic homeostasis during the uremic state, and 
endocrine support in the form of 1,25 Vitamin D3 may become an added benefit. 
Advancement of CFPD (ideally with a dialysate regeneration system based upon 
sorbent technology) that couples clearance of uremic toxins with perfusion to a cell 
therapy device, such as the BRECS, embodies a feasible approach to a wearable 
bioartificial kidney for treatment of ESRD. 
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